Building Leadership Economics

During FY11-12, pharmaceutical companies faced a tough marketplace and operating environment–deepening debt crises in US and Europe, chaotic currency markets and slower global economic growth having a profound impact on the business landscape. Increasing pressure on government budgets also weighed heavily on healthcare markets. Against this challenging background, Bilcare with disciplined execution, global footprint and focused strategy of solutions based leadership initiatives, delivered a good performance.

Today, we are global leaders in the pharmaceutical packaging industry with a sound presence worldwide. We have expanded and deepened our solution offerings; especially, with Bilcare nonClonableID® Technologies, our offering is creating an impact as an integrated player for Pharma brand growth in the highly demanding global pharmaceutical markets.

We will continue our value creation and excellence through the pharmaceutical packaging business by working with global Pharmacos on a wide range of specialty primary packaging materials and solutions including product specific research and brand-building package designs. Through the European and American acquisition, we have strengthened our presence in key geographies and aggressively rebuilt our product and solutions pipeline. Our growth strategies have enabled us to emerge as one of the largest packaging solutions company in the world. Today, 80% of our revenues come from international markets and it gives me pride to share that we are now a truly global company.

Integrated operations have enabled us to move up the value chain into higher value-added products and services through vertical integration of various business lines. Through innovation, we have introduced new products in the market and our focus of continuously improving our processes and multiple technologies has resulted in increased revenues and improved margins. I firmly believe that we will continue our leadership through technology and innovation. We will leverage our local presence and customer proximity in our key markets to work more closely with our customers in addressing jointly identified growth opportunities, providing enduring growth prospects for Bilcare and a win–win scenario for our customers.

Our investments in innovation, R&D and technology during the year led to strengthening our patent portfolio and addressing the critical challenges of our customers. Our products and solutions enable the end-user to verify genuineness of the products they have purchased, eliminating brand infiltration and enhanced control over supply chain and logistics. We are confident of our research applications reaching the common man given its tamper-proof nature and ease of use. Though the success of the go-to-market strategy has had its initial teething trouble, the newly evolved model will now empower the patients directly to check the medicine authentication and I see immense prospects for its growth as well as benefit to patients.

Next